Stock of the Day

December 11, 2020

Seer (SEER)

$2.17
+$0.01 (+0.5%)
Market Cap: $118.76M

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Today's Trend

Seer, Inc. (NASDAQ: SEER) shares are under pressure after a busy earnings day that included mixed quarterly results, a reaffirmed full-year outlook, a new patent lawsuit, and renewed takeover interest from minority holders. The stock has been drifting lower as investors weigh near-term revenue softness against possible strategic upside.

Overall, SEER is being pulled between encouraging strategic developments and a weaker-than-expected revenue print, with the earnings miss on sales appearing to be the biggest drag on the stock today.

Recent News